Archived: 12th Winter Conference
on Medicinal & Bioorganic Chemistry
January 25th - 29th 2015
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 25th 2015
Innovations in Drug Candidate Development
Program Chair: Pat Verhoest, Pfizer
Improving the Odds of Compound Survival in Neuroscience
Discovery of Highly Potent, Selective and Brain-Penetrant LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Beta-Secretase (BACE1) Inhibitors for the Treatment of Alzheimer’s Disease
Allosteric Modulation of Muscarinic Receptors
Monday, January 26th 2015
Perfecting Directed Aromatic and Heteroaromatic Ring Functionalization
Program Chair: Victor Snieckus, Queen’s University
Leveraging Emerging C-H Functionalization Chemistries for Efficient Diversification of Medicinally Important Heterocycles
Novel Methods for Synthesis and C-H Functionalization of Arenes and Heteroarenes
Cu(I)-Catalyzed Arene Functionalization via 1,3-Halogen Migration
Recent Developments in the Sulfination of (Hetero) Aromatic Rings: Direct Access to Sulfones and Sulfonamides of Medicinal Chemistry Relevance.
Recent Innovations in Medicinal and Bioorganic Chemistry
Program Chair: Mike VanNieuwenhze, Indiana University
Cascade Polyketide and Polyene Cyclizations: Biomimetic Total Synthesis of Hongoquercin B
Route Development for the Synthesis of EML4-ALK Inhibitor PF-06463922
Lipo-Peptide Glycoconjugates for Targeting Antigen Presenting Cells
Identification of GLP-1 Secretagogues – Targeting Type 2 Diabetes Mellitus
Targeting PI3Kd for Inflammation: Discovery and In Vivo Evaluation AMG319 and Related Inhibitors
Hit‐to‐lead Medicinal Chemistry for African Sleeping Sickness: An Invitation to Shared Hit‐to‐Lead Medicinal Chemistry Pursuit of Chemotypes Identified from a Kinase‐Targeted High‐Throughput Screening Campaign.
Tuesday, January 27th 2015
Mitigating Drug Induced Liver Injury (DILI) In Drug Discovery
Program Chair: Bryan Norman, Eli Lilly
Mechanism Based Translational Biomarkers for the Prediction of Drug Induced Liver Injury
Reactive Metabolites in Drug-Induced Liver Injury
Inhibition of Hepatobiliary Transporters in Drug-Induced Liver Injury
A Chemoproteomic Platform for Profiling the Targets of Reactive Drug Metabolites
Frontiers in Synthesis
Program Chair: Anthony G.M. Barrett, Imperial College
Histone Methyltransferase Inhibitors: Fast acting Molecules against Blood and Liver Stage Malaria Parasites
Dendritic Vaccine Delivery Systems
Application of PET and SPECT Radiotracers in Drug Development
Drug Discovery Efforts towards the Identification of Potent and Selective Tankyrase Inhibitors
Drug Discovery and Development by Design: Using the Knowledge from every Organic Crystal Structure Ever Published
Development of a Novel Class of Small Molecules used to Potentiate Tumor-Specific Oncolytic Virus Infection
Novel Chemical Probes for Use in the Study of Peptidoglycan Biosynthesis
Tetrazolone as an Acid Bioisostere: ‘Clickable’ Synthesis & Applications to Marketed Drugs
Wednesday, January 28th 2015
Advances in Cellular Readouts of Target Engagement and Cell Signaling Pathway Analysis
Program Chair: Daniel Flynn, Deciphera
Monitoring Target Engagement and Signaling Pathways through Chemoproteomic Interrogation of Nucleotide Binding Space
Monitoring Target Engagement using the Cellular Thermal Shift Assay for Lead Drug Development, Drug Deorphanization and Off-Target Studies
Simultaneous Analysis of Cancer Pathway Deregulation (Tumor-Centric) and Cancer Immune Response (Host-Centric)
Understanding and Overcoming the Vagaries of Target Engagement within the Ras-RAF-MEK-ERK Signalling Pathway
Strategies and Novel Platforms for Hit Seeking in Drug Discovery
Program Chair: Matthew M. Hayward, Pfizer
ALIS Affinity Selection in Pharmaceutical Discovery
Discovery of a Novel Mechanism for the Regulation of Apolipoprotein E
Application of Encoded Library Technology (ELT): From Library Design to the Clinic
Discovery and Development of Irreversible Inhibitors Targeting the Serine-hydrolase Superfamily
Thursday, January 29th 2015
Emerging Therapies for Hepatitis C
Program Chair: Philippe G. Nantermet, Merck
H2L 2020
Integrating Design, Analysis, and Visualization into the Phenotoypic Drug Discovery Workflow
From Old Targets to New, The Power of FBLG to Generate Novel Chemical Equity for Important Drug Targets
Discovery of Novel PDE10 Inhibitors for the Treatment of Schizophrenia Enabled by Parallel Hit-to-Lead Efforts
KEYNOTE PRESENTATION
Program Chair: Professor Anthony GM Barrett
Activity-Based Proteomics – Applications for Enzyme and Inhibitor Discovery
Media Sponsors


